Combination Treatment with Ionising Radiation and Gefitinib ('Iressa', ZD1839), an Epidermal Growth Factor Receptor (EGFR) Inhibitor, Significantly Inhibits Bladder Cancer Cell Growth in vitro and in vivo

• Material Type: 記事
• Title: Combination Treatment with Ionising Radiation and Gefitinib ('Iressa', ZD1839), an Epidermal Growth Factor Receptor (EGFR) Inhibitor, Significantly Inhibits Bladder Cancer Cell Growth in vitro and in vivo
• Title Transcription: Combination Treatment with Ionising Radiation and Gefitinib ('Iressa', ZD1839), an Epidermal Growth Factor Receptor (EGFR) Inhibitor, Significantly Inhibits Bladder Cancer Cell Growth in vitro and in vivo
• Author/Editor: COLQUHOUN,AJ; MCHUGH,LA; TULCHINSKY,E.; KRIAJEVSKA,M.; MELLON,JK
• Publication, Distribution, etc.: 日本 : the Japan Radiation Research Society
• Publication Date: 2007-09-15
• Publication Date (W3CDTF): 2007-09-15
• Periodical title: Journal of radiation research
• No. or year of volume/issue: 48(5)
• Volume: 48(5)
• Pages: 351-360
• Text Language Code: ENG
• Subject Heading: Tyrosine kinase inhibitors; Radiotherapy; Invasive bladder cancer; Radiosensitizing agents
• Note (General): 著者所属: Department of Cancer Studies and Molecular Medicine, Clinical Sciences Unit, Leicester General Hospital
• Persistent ID (NDL): info:ndljp/pid/10918956; https://dl.ndl.go.jp/pid/10918956
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > 学術機関 > 学協会; https://dl.ndl.go.jp/collections/B00043
• Acquisition Basis: NII-ELS
• Available (W3CDTF): 2017-08-30
• Date Accepted (W3CDTF): 2017-08-22
• Date Captured (W3CDTF): 2017-08-22
• Format (IMT): application/pdf
• Access Restrictions: インターネット公開
• Availability of remote photoduplication service: 不可
• Periodical Title (Persistent ID (NDL)): info:ndljp/pid/10399870; https://dl.ndl.go.jp/pid/10399870
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

• Summary, etc.: Purpose : External beam radiotherapy (EBRT) is the principal bladder-preserving monotherapy for muscle-invasive bladder cancer. Seventy percent of mus...